Samuel R. Denmeade, M.D. - Publications

Affiliations: 
Johns Hopkins University, Baltimore, MD 
Area:
Pharmacology, Biochemistry, Oncology
Website:
https://www.hopkinsmedicine.org/pharmacology_molecular_sciences/faculty/bios/denmeade.html

146 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33958727 DOI: 10.1038/s41388-021-01805-6  0.8
2021 Christensen SB, Simonsen HT, Engedal N, Nissen P, Møller JV, Denmeade SR, Isaacs JT. From Plant to Patient: Thapsigargin, a Tool for Understanding Natural Product Chemistry, Total Syntheses, Biosynthesis, Taxonomy, ATPases, Cell Death, and Drug Development. Progress in the Chemistry of Organic Natural Products. 115: 59-114. PMID 33797641 DOI: 10.1007/978-3-030-64853-4_2  0.6
2021 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Correction to: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 33564077 DOI: 10.1038/s41388-021-01640-9  0.8
2020 Sena LA, Wang H, Lim ScM SJ, Rifkind I, Ngomba N, Isaacs JT, Luo J, Pratz C, Sinibaldi V, Carducci MA, Paller CJ, Eisenberger MA, Markowski MC, Antonarakis ES, Denmeade SR. Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. European Journal of Cancer (Oxford, England : 1990). 144: 302-309. PMID 33383350 DOI: 10.1016/j.ejca.2020.11.043  0.6
2020 Brennen WN, J Thorek DL, Jiang W, Krueger TE, Antony L, Denmeade SR, Isaacs JT. Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy. Immunotherapy. PMID 33148078 DOI: 10.2217/imt-2020-0066  0.8
2020 Zhu Y, Dalrymple SL, Coleman I, Zheng SL, Xu J, Hooper JE, Antonarakis ES, De Marzo AM, Meeker AK, Nelson PS, Isaacs WB, Denmeade SR, Luo J, Brennen WN, Isaacs JT. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene. PMID 32989253 DOI: 10.1038/s41388-020-01479-6  0.8
2020 Rogers OC, Antony L, Levy O, Joshi N, Simons BW, Dalrymple S, Rosen M, Pickering A, Lan H, Kuang H, Ranganath SH, Zheng L, Karp JM, Howard SP, Denmeade SR, et al. Microparticle Encapsulation of a Prostate-Targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. PMID 32943549 DOI: 10.1158/1535-7163.Mct-20-0227  0.8
2019 Isaacs JT, Brennen WN, Denmeade SR. Serial bipolar androgen therapy (sBAT) using cyclic supraphysiologic testosterone (STP) to treat metastatic castration-resistant prostate cancer (mCRPC). Annals of Translational Medicine. 7: S311. PMID 32016030 DOI: 10.21037/Atm.2019.10.32  0.8
2019 Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR. In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Translational Medicine. PMID 30925030 DOI: 10.1002/Sctm.19-0068  0.8
2019 Akinboye ES, Brennen WN, Denmeade SR, Isaacs JT. Albumin-linked prostate-specific antigen-activated thapsigargin- and niclosamide-based molecular grenades targeting the microenvironment in metastatic castration-resistant prostate cancer. Asian Journal of Urology. 6: 99-108. PMID 30775253 DOI: 10.1016/J.Ajur.2018.11.004  0.8
2019 Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR. A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. Stem Cells Translational Medicine. PMID 30735000 DOI: 10.1002/Sctm.18-0230  0.8
2019 Mendonca J, Owoyemi O, Rosen M, Carducci M, Markowski M, Antonarakis E, Pardoll D, Denmeade S, Kachhap SK. Abstract 517: Supraphysiological androgens activate innate immune signaling in prostate cancer Immunology. DOI: 10.1158/1538-7445.Sabcs18-517  0.44
2018 Krueger TEG, Thorek DLJ, Denmeade SR, Isaacs JT, Brennen WN. Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Translational Medicine. PMID 30070053 DOI: 10.1002/Sctm.18-0024  0.8
2018 Rogers OC, Anthony L, Rosen DM, Brennen WN, Denmeade SR. PSA-selective activation of cytotoxic human serine proteases within the tumor microenvironment as a therapeutic strategy to target prostate cancer. Oncotarget. 9: 22436-22450. PMID 29854290 DOI: 10.18632/Oncotarget.25091  0.8
2018 Kostova MB, Brennen WN, Lopez D, Anthony L, Wang H, Platz E, Denmeade SR. PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones. The Prostate. PMID 29659051 DOI: 10.1002/Pros.23539  0.8
2017 Akinboye ES, Rosen MD, Bakare O, Denmeade SR. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives. Bioorganic & Medicinal Chemistry. PMID 29153549 DOI: 10.1016/J.Bmc.2017.11.015  0.56
2017 Isaacs JT, Brennen WN, Denmeade SR. Rationale for Bipolar Androgen Therapy (BAT) for Metastatic Prostate Cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 28820291 DOI: 10.1080/15384101.2017.1360645  0.8
2017 Brennen WN, Zhang B, Kulac I, Kisteman LN, Antony L, Wang H, Meeker AK, De Marzo AM, Garraway IP, Denmeade SR, Isaacs JT. Mesenchymal stem cell infiltration during neoplastic transformation of the human prostate. Oncotarget. PMID 28493842 DOI: 10.18632/Oncotarget.17362  0.8
2016 Paller CJ, Denmeade SR, Carducci MA. Challenges of conducting clinical trials of natural products to combat cancer. Clinical Advances in Hematology & Oncology : H&O. 14: 447-55. PMID 27379814  0.88
2016 Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR. Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study. The Prostate. PMID 27338150 DOI: 10.1002/Pros.23209  0.88
2016 Sangster-Guity N, Tu-Sekine B, Raben DM, Denmeade SR, Williams SA. Mutational analysis of prostate-specific antigen defines the intrinsic proteolytic activity of the proPSA zymogen. The Prostate. PMID 27273171 DOI: 10.1002/Pros.23216  0.36
2016 Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. British Journal of Cancer. 114: 986-94. PMID 27115568 DOI: 10.1038/Bjc.2016.72  0.88
2016 Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 91: 140-150. PMID 27019026 DOI: 10.1016/J.Biomaterials.2016.03.023  0.88
2016 Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. The Prostate. PMID 26835873 DOI: 10.1002/Pros.23162  0.8
2016 Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy Prostate. DOI: 10.1002/pros.23162  0.88
2015 Akinboye ES, Bamji ZD, Kwabi-Addo B, Ejeh D, Copeland RL, Denmeade SR, Bakare O. Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines. Bioorganic & Medicinal Chemistry. 23: 5839-45. PMID 26187015 DOI: 10.1016/J.Bmc.2015.06.072  0.88
2015 Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA. A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. The Prostate. PMID 26012728 DOI: 10.1002/Pros.23024  0.88
2015 Barakat DJ, Zhang J, Barberi T, Denmeade SR, Friedman AD, Paz-Priel I. CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells. Oncogene. PMID 25772238 DOI: 10.1038/Onc.2015.41  0.88
2015 Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Science Translational Medicine. 7: 269ra2. PMID 25568070 DOI: 10.1126/Scitranslmed.3010563  0.88
2015 LeBeau AM, Denmeade SR. Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Molecular Cancer Therapeutics. 14: 659-68. PMID 25537662 DOI: 10.1158/1535-7163.Mct-14-0744  0.88
2015 Doan NT, Paulsen ES, Sehgal P, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Dionne CA, Christensen SB. Targeting thapsigargin towards tumors. Steroids. 97: 2-7. PMID 25065587 DOI: 10.1016/J.Steroids.2014.07.009  0.88
2015 Teply BA, Luber B, Denmeade SR, Antonarakis ES. The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer Prostate Cancer and Prostatic Diseases. DOI: 10.1038/Pcan.2015.53  0.88
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, ... ... Denmeade SR, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. The New England Journal of Medicine. 371: 1028-38. PMID 25184630 DOI: 10.1056/Nejmoa1315815  0.88
2014 Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES. Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. The Prostate. 74: 1560-8. PMID 25176007 DOI: 10.1002/Pros.22874  0.88
2014 Brennen WN, Rosen DM, Chaux A, Netto GJ, Isaacs JT, Denmeade SR. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. The Prostate. 74: 1308-19. PMID 25053236 DOI: 10.1002/Pros.22847  0.88
2014 Paller CJ, Olatoye D, Xie S, Zhou X, Denmeade SR, Eisenberger MA, Antonarakis ES, Carducci MA, Rosner GL. The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer Prostate Cancer and Prostatic Diseases. 17: 28-33. PMID 24100642 DOI: 10.1038/pcan.2013.40  0.88
2014 Brennen WN, Levy O, Ranganath S, Schweizer M, Rosen M, Billet S, Bhowmick N, Denmeade S, Karp J, Isaacs J. Abstract 699: Mesenchymal stem cells (MSC) as cell-based vectors for PSA-activated proaerolysin to sites of prostate cancer Cancer Research. 74: 699-699. DOI: 10.1158/1538-7445.Am2014-699  0.8
2014 Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Fedor HL, Lotan TL, Marzo AMD, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, et al. Abstract 2910: Androgen receptor splice variant-7 predicts resistance to enzalutamide in patients with castration-resistant prostate cancer Cancer Research. 74: 2910-2910. DOI: 10.1158/1538-7445.Am2014-2910  0.6
2013 Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocrine-Related Cancer. 20: R269-90. PMID 23975882 DOI: 10.1530/Erc-13-0151  0.88
2013 Kostova MB, Rosen DM, Chen Y, Mease RC, Denmeade SR. Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors. Journal of Medicinal Chemistry. 56: 4224-35. PMID 23692593 DOI: 10.1021/Jm301718C  0.88
2013 Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, et al. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Research. 73: 3248-61. PMID 23580570 DOI: 10.1158/0008-5472.Can-12-1578  0.88
2013 Manning ML, Williams SA, Jelinek CA, Kostova MB, Denmeade SR. Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasma. Journal of Immunology (Baltimore, Md. : 1950). 190: 2567-74. PMID 23401592 DOI: 10.4049/Jimmunol.1200856  0.88
2013 Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 4: 106-17. PMID 23362217 DOI: 10.18632/Oncotarget.805  0.88
2013 Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. The Journal of Urology. 189: 1421-6. PMID 23142202 DOI: 10.1016/J.Juro.2012.11.003  0.88
2013 Nam S, Sangster-Guity N, Ewachiw TE, Denmeade SR, Williams SA. Abstract 5058: Expansion and validation of the prostate-specific antigen substrate degradome. Cancer Research. 73: 5058-5058. DOI: 10.1158/1538-7445.Am2013-5058  0.36
2012 Brennen WN, Rosen DM, Wang H, Isaacs JT, Denmeade SR. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute. 104: 1320-34. PMID 22911669 DOI: 10.1093/Jnci/Djs336  0.88
2012 Akinboye ES, Rosen MD, Denmeade SR, Kwabi-Addo B, Bakare O. Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer. Journal of Medicinal Chemistry. 55: 7450-9. PMID 22867001 DOI: 10.1021/Jm300426Q  0.88
2012 Denmeade SR, Isaacs JT. Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget. 3: 666-7. PMID 22837432 DOI: 10.18632/Oncotarget.562  0.88
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, Demarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science Translational Medicine. 4: 140ra86. PMID 22745436 DOI: 10.1126/Scitranslmed.3003886  0.88
2012 Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2714-9. PMID 22553195 DOI: 10.1093/Annonc/Mds078  0.88
2012 Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. The Prostate. 72: 1491-505. PMID 22396319 DOI: 10.1002/Pros.22504  0.88
2012 Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular Cancer Therapeutics. 11: 257-66. PMID 22323494 DOI: 10.1158/1535-7163.Mct-11-0340  0.88
2012 Manning ML, Kostova M, Williams SA, Denmeade SR. Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid. The Prostate. 72: 1233-8. PMID 22213008 DOI: 10.1002/Pros.22474  0.88
2012 Antonarakis ES, Carducci MA, Eisenberger MA, Denmeade SR, Slovin SF, Jelaca-Maxwell K, Vincent ME, Scher HI, Morris MJ. Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial. Cancer Chemotherapy and Pharmacology. 69: 763-71. PMID 22020316 DOI: 10.1007/S00280-011-1759-9  0.88
2012 Brandy Y, Ononiwu I, Adedeji D, Williams V, Mouamba C, Kanaan Y, Copeland RL, Wright DA, Butcher RJ, Denmeade SR, Bakare O. Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines. Investigational New Drugs. 30: 1709-14. PMID 21243402 DOI: 10.1007/S10637-011-9635-3  0.88
2012 Chen S, Brennen N, Brodsky RA, Cheng L, Denmeade SR, Isaacs JT. Abstract 5699: Mesenchymal stem cells (MSCs) as a selective delivery vehicle for a PSA-activated protoxin for advanced prostate cancer Cancer Research. 72: 5699-5699. DOI: 10.1158/1538-7445.Am2012-5699  0.6
2012 Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, et al. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy (Science Translational Medicine) Science Translational Medicine. 4. DOI: 10.1126/Scitranslmed.3004546  0.88
2011 Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Walczak J, Eisenberger MA. The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation Prostate. 71: 1608-1615. PMID 21432863 DOI: 10.1002/Pros.21377  0.88
2011 Williams SA, Jelinek CA, Litvinov I, Cotter RJ, Isaacs JT, Denmeade SR. Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. The Prostate. 71: 1595-607. PMID 21394741 DOI: 10.1002/Pros.21375  0.88
2011 Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. European Urology. 59: 747-54. PMID 21129846 DOI: 10.1016/J.Eururo.2010.11.024  0.88
2010 Hu R, Denmeade SR, Luo J. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Review of Endocrinology & Metabolism. 5: 753-764. PMID 21318111 DOI: 10.1586/Eem.10.49  0.88
2010 Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5269-76. PMID 20978144 DOI: 10.1158/1078-0432.Ccr-10-1928  0.88
2010 Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. The Prostate. 70: 1600-7. PMID 20607766 DOI: 10.1002/Pros.21196  0.88
2010 Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH, Weber DJ, Bachman KE. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene. 29: 4715-24. PMID 20562907 DOI: 10.1038/Onc.2010.220  0.88
2010 LeBeau AM, Kostova M, Craik CS, Denmeade SR. Prostate-specific antigen: an overlooked candidate for the targeted treatment and selective imaging of prostate cancer. Biological Chemistry. 391: 333-43. PMID 20180648 DOI: 10.1515/Bc.2010.044  0.88
2010 Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1496-501. PMID 20159814 DOI: 10.1200/Jco.2009.25.9259  0.88
2010 Williams SA, Xu Y, De Marzo AM, Isaacs JT, Denmeade SR. Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. The Prostate. 70: 788-96. PMID 20058238 DOI: 10.1002/Pros.21111  0.88
2010 Williams SA, Jelinek CA, Cotter RJ, Isaacs JT, Denmeade SR. Abstract 2326: Loss of prostate-specific antigen slows growth and alters the extracellular proteome of LNCaP human prostate cancer cells Cancer Research. 70: 2326-2326. DOI: 10.1158/1538-7445.Am10-2326  0.6
2010 Brennen WN, Rosen M, Denmeade SR. Abstract 1424: Fibroblast activation protein alpha (FAP): Targeting the reactive stroma as a novel prodrug therapy Cancer Research. 70: 1424-1424. DOI: 10.1158/1538-7445.Am10-1424  0.8
2009 Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, et al. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7099-105. PMID 19887483 DOI: 10.1158/1078-0432.Ccr-09-1722  0.88
2009 Singh P, LeBeau AM, Lilja H, Denmeade SR, Isaacs JT. Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins. 77: 984-93. PMID 19705489 DOI: 10.1002/Prot.22524  0.88
2009 LeBeau AM, Banerjee SR, Pomper MG, Mease RC, Denmeade SR. Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancer. Bioorganic & Medicinal Chemistry. 17: 4888-93. PMID 19541487 DOI: 10.1016/J.Bmc.2009.06.012  0.88
2009 LeBeau AM, Brennen WN, Aggarwal S, Denmeade SR. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Molecular Cancer Therapeutics. 8: 1378-86. PMID 19417147 DOI: 10.1158/1535-7163.Mct-08-1170  0.88
2009 Vander Griend DJ, Antony L, Dalrymple SL, Xu Y, Christensen SB, Denmeade SR, Isaacs JT. Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Molecular Cancer Therapeutics. 8: 1340-9. PMID 19417145 DOI: 10.1158/1535-7163.Mct-08-1136  0.88
2009 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry. 48: 3490-6. PMID 19281249 DOI: 10.1021/Bi9001858  0.88
2009 Christensen SB, Skytte DM, Denmeade SR, Dionne C, Møller JV, Nissen P, Isaacs JT. A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anti-Cancer Agents in Medicinal Chemistry. 9: 276-94. PMID 19275521 DOI: 10.2174/1871520610909030276  0.88
2009 Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proceedings of the National Academy of Sciences of the United States of America. 106: 2835-40. PMID 19196980 DOI: 10.1073/Pnas.0813351106  0.88
2009 Chandran SS, Williams SA, Denmeade SR. Extended-release PEG-luciferin allows for long-term imaging of firefly luciferase activity in vivo. Luminescence : the Journal of Biological and Chemical Luminescence. 24: 35-8. PMID 18780328 DOI: 10.1002/Bio.1060  0.88
2008 Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biology & Therapy. 7: 974-82. PMID 18698158 DOI: 10.4161/Cbt.7.6.5968  0.88
2008 Singla A, Denmeade SR. Left posterior fascicular block due to high-dose interleukin-2. The Annals of Pharmacotherapy. 42: 1340-3. PMID 18664608 DOI: 10.1345/Aph.1K669  0.88
2008 LeBeau AM, Singh P, Isaacs JT, Denmeade SR. Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chemistry & Biology. 15: 665-74. PMID 18635003 DOI: 10.1016/J.Chembiol.2008.05.020  0.88
2008 Rathkopf D, Carducci MA, Morris MJ, Slovin SF, Eisenberger MA, Pili R, Denmeade SR, Kelsen M, Curley T, Halter M, Collins C, Fleisher M, Heller G, Baker SD, Scher HI. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2959-65. PMID 18565882 DOI: 10.1200/Jco.2007.15.1928  0.88
2008 Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 47: 1076-86. PMID 18095711 DOI: 10.1021/Bi701921B  0.88
2008 Singh P, Williams SA, Shah MH, Lectka T, Pritchard GJ, Isaacs JT, Denmeade SR. Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins. 70: 1416-28. PMID 17894328 DOI: 10.1002/Prot.21676  0.88
2007 Chandran SS, Nan A, Rosen DM, Ghandehari H, Denmeade SR. A prostate-specific antigen activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer. Molecular Cancer Therapeutics. 6: 2928-37. PMID 18025277 DOI: 10.1158/1535-7163.Mct-07-0392  0.88
2007 Kachhap SK, Faith D, Qian DZ, Shabbeer S, Galloway NL, Pili R, Denmeade SR, DeMarzo AM, Carducci MA. The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin. Plos One. 2: e844. PMID 17786215 DOI: 10.1371/Journal.Pone.0000844  0.88
2007 Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, Pili R, Sinibaldi VJ, Walczak JS, Denmeade SR. Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biology & Therapy. 6: 1360-7. PMID 17786033 DOI: 10.4161/Cbt.6.9.4541  0.88
2007 Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-Cancer Drugs. 18: 809-16. PMID 17581303 DOI: 10.1097/Cad.0B013E3280Bad82D  0.88
2007 Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorganic & Medicinal Chemistry. 15: 4973-84. PMID 17502149 DOI: 10.1016/J.Bmc.2007.04.029  0.88
2007 Bajaj GK, Zhang Z, Garrett-Mayer E, Drew R, Sinibaldi V, Pili R, Denmeade SR, Carducci MA, Eisenberger MA, DeWeese TL. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Urology. 69: 526-31. PMID 17382158 DOI: 10.1016/J.Urology.2006.12.006  0.88
2007 Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. Journal of the National Cancer Institute. 99: 376-85. PMID 17341729 DOI: 10.1093/Jnci/Djk065  0.88
2007 Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? The Prostate. 67: 312-29. PMID 17143882 DOI: 10.1002/Pros.20531  0.88
2006 Liu H, Jensen KG, Tran LM, Chen M, Zhai L, Olsen CE, Søhoel H, Denmeade SR, Isaacs JT, Christensen SB. Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica. Phytochemistry. 67: 2651-8. PMID 17098264 DOI: 10.1016/J.Phytochem.2006.10.005  0.88
2006 Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR. A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Research. 66: 9171-7. PMID 16982760 DOI: 10.1158/0008-5472.Can-06-1520  0.92
2006 Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT. Combinatorial androgen receptor targeted therapy for prostate cancer. Endocrine-Related Cancer. 13: 653-66. PMID 16954423 DOI: 10.1677/Erc.1.00797  0.88
2006 Sinibaldi VJ, Elza-Brown K, Schmidt J, Eisenberger MA, Rosenbaum E, Denmeade SR, Pili R, Walczak J, Baker SD, Zahurak M, Carducci MA. Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma American Journal of Clinical Oncology: Cancer Clinical Trials. 29: 395-398. PMID 16891869 DOI: 10.1097/01.Coc.0000225411.95479.B4  0.88
2006 Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4072-9. PMID 16818707 DOI: 10.1158/1078-0432.Ccr-06-0184  0.88
2006 Aggarwal S, Harden JL, Denmeade SR. Synthesis and screening of a random dimeric peptide library using the one-bead-one-dimer combinatorial approach. Bioconjugate Chemistry. 17: 335-40. PMID 16536463 DOI: 10.1021/Bc0502659  0.88
2006 Aggarwal S, Ricklis RM, Williams SA, Denmeade SR. Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. The Prostate. 66: 903-10. PMID 16496413 DOI: 10.1002/Pros.20413  0.88
2006 Søhoel H, Jensen AM, Møller JV, Nissen P, Denmeade SR, Isaacs JT, Olsen CE, Christensen SB. Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorganic & Medicinal Chemistry. 14: 2810-5. PMID 16412648 DOI: 10.1016/J.Bmc.2005.12.001  0.88
2006 Janssen S, Rosen DM, Ricklis RM, Dionne CA, Lilja H, Christensen SB, Isaacs JT, Denmeade SR. Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. The Prostate. 66: 358-68. PMID 16302271 DOI: 10.1002/Pros.20348  0.88
2006 Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 91: 79-84. PMID 16263812 DOI: 10.1210/Jc.2005-1882  0.88
2006 Carducci MA, Denmeade SR. Advances in the understanding and treatment of prostate cancer Advanced Studies in Medicine. 6.  0.88
2005 Aggarwal S, Janssen S, Wadkins RM, Harden JL, Denmeade SR. A combinatorial approach to the selective capture of circulating malignant epithelial cells by peptide ligands. Biomaterials. 26: 6077-86. PMID 15907998 DOI: 10.1016/J.Biomaterials.2005.03.040  0.88
2005 Singh P, Mhaka AM, Christensen SB, Gray JJ, Denmeade SR, Isaacs JT. Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. Journal of Medicinal Chemistry. 48: 3005-14. PMID 15828839 DOI: 10.1021/Jm049319A  0.88
2005 Denmeade SR, Isaacs JT. The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biology & Therapy. 4: 14-22. PMID 15662118 DOI: 10.4161/Cbt.4.1.1505  0.88
2004 Janssen S, Jakobsen CM, Rosen DM, Ricklis RM, Reineke U, Christensen SB, Lilja H, Denmeade SR. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. Molecular Cancer Therapeutics. 3: 1439-50. PMID 15542783  0.88
2004 Mhaka A, Gady AM, Rosen DM, Lo KM, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biology & Therapy. 3: 551-8. PMID 15044850 DOI: 10.4161/Cbt.3.6.846  0.88
2004 Denmeade SR, Isaacs JT. The role of prostate-specific antigen in the clinical evaluation of prostatic disease. Bju International. 93: 10-5. PMID 15009080 DOI: 10.1111/J.1464-410X.2003.04634.X  0.88
2004 Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, Carducci MA. A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma Journal of Interferon and Cytokine Research. 24: 37-41. PMID 14980083 DOI: 10.1089/107999004772719891  0.88
2004 Lapidus RG, Dang W, Rosen DM, Gady AM, Zabelinka Y, O'Meally R, DeWeese TL, Denmeade SR. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation. The Prostate. 58: 291-8. PMID 14743469 DOI: 10.1002/Pros.10331  0.88
2004 Denmeade SR, Isaacs JT. Development of prostate cancer treatment: the good news. The Prostate. 58: 211-24. PMID 14743459 DOI: 10.1002/Pros.10360  0.88
2003 Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Research. 63: 5559-63. PMID 14500395  0.88
2003 Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. Journal of the National Cancer Institute. 95: 990-1000. PMID 12837835 DOI: 10.1093/Jnci/95.13.990  0.88
2003 Denmeade SR, Litvinov I, Sokoll LJ, Lilja H, Isaacs JT. Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. The Prostate. 56: 45-53. PMID 12746846 DOI: 10.1002/Pros.10213  0.88
2003 Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate. 54: 249-57. PMID 12539223 DOI: 10.1002/Pros.10199  0.88
2002 Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 12: 2459-61. PMID 12161157 DOI: 10.1016/S0960-894X(02)00433-X  0.88
2002 Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nature Reviews. Cancer. 2: 389-96. PMID 12044015 DOI: 10.1038/Nrc801  0.88
2002 Tombal B, Denmeade SR, Gillis JM, Isaacs JT. A supramicromolar elevation of intracellular free calcium ([Ca(2+)](i)) is consistently required to induce the execution phase of apoptosis. Cell Death and Differentiation. 9: 561-73. PMID 11973614 DOI: 10.1038/Sj.Cdd.4400999  0.88
2002 Pinski J, Weeraratna A, Uzgare AR, Arnold JT, Denmeade SR, Isaacs JT. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Research. 62: 986-9. PMID 11861369  0.88
2001 Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. Journal of Medicinal Chemistry. 44: 4696-703. PMID 11741487 DOI: 10.1021/Jm010985A  0.88
2001 Weeraratna AT, Dalrymple SL, Lamb JC, Denmeade SR, Miknyoczki S, Dionne CA, Isaacs JT. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 7: 2237-45. PMID 11489797  0.88
2001 Denmeade SR, Lövgren J, Khan SR, Lilja H, Isaacs JT. Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. The Prostate. 48: 122-6. PMID 11433422 DOI: 10.1002/Pros.1088  0.88
2001 Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Rapid communication: Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models Prostate. 48: 1-6. PMID 11391681 DOI: 10.1002/Pros.1075  0.88
2001 Denmeade SR, Tombal B, Isaacs JT. Apoptotic pathways in prostate cancer Advances in Cell Aging and Gerontology. 6: 23-54. DOI: 10.1016/S1566-3124(01)06002-3  0.88
2000 Gala JL, Loric S, Guiot Y, Denmeade SR, Gady A, Brasseur F, Heusterspreute M, Eschwege P, De Nayer P, Van Cangh P, Tombal B. Expression of Prostate-specific membrane antigen in transitional cell carcinoma of the bladder: Prognostic value? Clinical Cancer Research. 6: 4049-4054. PMID 11051255  0.88
2000 Khan SR, Denmeade SR. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts Prostate. 45: 80-83. PMID 10960846 DOI: 10.1002/1097-0045(20000915)45:1<80::Aid-Pros10>3.0.Co;2-Q  0.88
2000 Jackisch C, Hahm HA, Tombal B, McCloskey D, Butash K, Davidson NE, Denmeade SR. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 2844-50. PMID 10914733  0.88
2000 Tombal B, Weeraratna AT, Denmeade SR, Isaacs JT. Thapsigargin induces a calmodulin/calcineurin-dependent apoptotic cascade responsible for the death of prostatic cancer cells Prostate. 43: 303-317. PMID 10861750 DOI: 10.1002/1097-0045(20000601)43:4<303::Aid-Pros10>3.0.Co;2-V  0.88
2000 Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: What went wrong? Journal of Urology. 164: 3-9. PMID 10840412 DOI: 10.1016/S0022-5347(05)67436-8  0.88
1999 Denmeade SR, Lin XS, Tombal B, Isaacs JT. Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells. The Prostate. 39: 269-79. PMID 10344216 DOI: 10.1002/(Sici)1097-0045(19990601)39:4<269::Aid-Pros7>3.0.Co;2-F  0.88
1999 Tombal B, Denmeade SR, Isaacs JT. Assessment and validation of a microinjection method for kinetic analysis of [Ca2+](i) in individual cells undergoing apoptosis Cell Calcium. 25: 19-28. PMID 10191957 DOI: 10.1054/Ceca.1998.0005  0.88
1999 Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett C, Isaacs JT. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2 Prostate. 38: 46-54. PMID 9973109 DOI: 10.1002/(Sici)1097-0045(19990101)38:1<46::Aid-Pros6>3.0.Co;2-9  0.88
1999 Denmeade SR. Apoptotic pathways in normal prostate and prostate cancers Prostate Journal. 1: 120-125. DOI: 10.1046/J.1525-1411.1999.09921.X  0.88
1998 Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate- specific antigen Cancer Research. 58: 2537-2540. PMID 9635575  0.88
1998 Denmeade SR, Isaacs JT. Enzymatic activation of prodrugs by prostate-specific antigen: Targeted therapy for metastatic prostate cancer Cancer Journal From Scientific American. 4: S15-S21. PMID 9619266  0.88
1997 Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 3: 2507-11. PMID 9815654  0.88
1997 Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. The Prostate. 33: 201-7. PMID 9365549 DOI: 10.1002/(Sici)1097-0045(19971101)33:3<201::Aid-Pros9>3.0.Co;2-L  0.88
1997 Denmeade SR, Lou W, Lövgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen Cancer Research. 57: 4924-4930. PMID 9354459  0.88
1997 Denmeade SR, McCloskey DE, Joseph IBJK, Hahm HA, Isaacs JT, Davidson NE. Apoptosis in Hormone-Responsive Malignancies Advances in Pharmacology. 41: 553-583. PMID 9204159 DOI: 10.1016/S1054-3589(08)61072-8  0.88
1997 Denmeade SR, Isaacs JT. Prostate cancer: Where are we and where are we going? British Journal of Urology, Supplement. 79: 2-7. PMID 9088266 DOI: 10.1111/J.1464-410X.1997.Tb00794.X  0.88
1996 Denmeade SR, Isaacs JT. Activation of Programmed (Apoptotic) Cell Death for the Treatment of Prostate Cancer Advances in Pharmacology. 35: 281-306. PMID 8920208 DOI: 10.1016/S1054-3589(08)60278-1  0.88
1996 Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. The Prostate. 28: 251-65. PMID 8602401 DOI: 10.1002/(Sici)1097-0045(199604)28:4<251::Aid-Pros6>3.0.Co;2-G  0.88
1996 Denmeade SR, Isaacs JT. Programmed cell death (apoptosis) and cancer chemotherapy Cancer Control. 3: 303-309. DOI: 10.1177/107327489600300401  0.88
1995 Lin XS, Denmeade SR, Isaacs JT. The genetics of programmed (apoptotic) cell death Cancer Surveys. 25: 173-194. PMID 8718518  0.88
1985 O'Krongly D, Denmeade SR, Chiang MY, Breslow R. Efficient triple coupling reaction to produce a self-adjusting molecular cage Journal of the American Chemical Society. 107: 5544-5545.  0.88
Show low-probability matches.